This design enables discrimination between route-dependent and route-independent therapeutic ef fects of ADSCs, thereby providing new insight into the optimization of stem cell delivery strategies for pulmo nary fibrosis. Importantly, whether the choice of deliv ery route differentially affects survival and inflammatory resolution, independent of antifibrotic efficacy, remains insufficiently addressed in current preclinical studies.
Ng et al. (Sat,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: